MNOV · XBRL financial data

Medicinova financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (MNOV's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	1,000	0*	—	—	—	—	—	135	123	152*	187	458
Research and development	700	1,600*	1,700	1,500	1,800	1,800*	1,700	2,000	1,500	1,400*	1,200	900
General and administrative	1,352	839*	1,354	1,400	1,450	1,276*	1,363	1,437	1,806	1,554*	1,590	1,830
Total operating expenses	2,147	2,490*	3,136	3,046	3,309	3,184*	3,203	3,742	3,504	3,244*	3,023	3,000
Operating income (loss)	(1,147)	(2,490)*	(3,136)	(3,046)	(3,309)	(3,184)*	(3,203)	(3,607)	(3,381)	(3,092)*	(2,836)	(2,541)
Other income (expense)	(14)	(2)*	(16)	(17)	9	(15)*	2	1	(10)	(6)*	(3)	(5)
Income tax expense (benefit)	—	year only	—	—	—	year only	—	—	—	year only	—	—
Net income (loss)	(723)	(2,059)*	(2,755)	(2,628)	(2,852)	(2,815)*	(2,864)	(3,281)	(3,050)	(2,802)*	(2,586)	(2,314)
Earnings per share, basic USD per share	(0.01)	(0.04)*	(0.06)	(0.05)	(0.06)	(0.06)*	(0.06)	(0.07)	(0.06)	(0.06)*	(0.05)	(0.05)
Earnings per share, diluted USD per share	(0.01)	(0.04)*	(0.06)	(0.05)	(0.06)	(0.06)*	(0.06)	(0.07)	(0.06)	(0.06)*	(0.05)	(0.05)
Weighted average shares, basic thousands of shares	49,046	49,046*	49,046	49,046	49,046	49,046*	49,046	49,046	49,046	49,114*	49,221	49,221
Weighted average shares, diluted thousands of shares	49,046	49,046*	49,046	49,046	49,046	49,046*	49,046	49,046	49,046	49,114*	49,221	49,221

Balance sheet

CSV

Fiscal quarters (MNOV's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	51,507	50,999	47,139	44,338	42,281	40,360	36,571	34,260	32,563	30,806	27,329	25,416
Accounts receivable	1,000	—	—	—	—	0	—	135	0	0	245	0
Prepaid and other current assets	489	175	725	1,168	985	715	1,108	730	360	185	572	506
Total current assets	52,996	51,174	47,864	45,506	43,265	41,074	37,679	35,124	32,923	30,991	28,146	25,921
Property and equipment, net	51	46	40	36	31	26	20	15	13	8	15	10
Right-of-use asset	618	575	519	443	404	357	312	265	224	184	144	102
Goodwill	9,600	9,600	9,600	9,600	9,600	9,600	9,600	9,600	9,600	9,600	9,600	9,600
Total assets	68,137	66,270	62,894	60,404	58,119	55,876	52,431	49,824	47,578	45,603	42,705	40,433
Accounts payable	737	1,004	805	668	708	1,102	719	569	746	625	852	951
Total current liabilities	2,802	3,279	2,510	2,494	2,597	2,959	2,134	2,648	3,337	3,798	3,096	2,961
Lease liability, non-current	464	411	351	302	255	211	165	117	74	17	0	0
Total liabilities	3,467	3,892	3,063	2,999	3,054	3,372	2,501	2,967	3,614	4,016	3,298	3,163
Accumulated deficit	(413,643)	(415,702)	(418,456)	(421,084)	(423,937)	(426,751)	(429,615)	(432,897)	(435,947)	(438,749)	(441,335)	(443,650)
Total stockholders' equity	64,669	62,378	59,830	57,405	55,066	52,504	49,930	46,857	43,965	41,587	39,407	37,271
Total liabilities and equity	68,137	66,270	62,894	60,404	58,119	55,876	52,431	49,824	47,578	45,603	42,705	40,433
Common shares outstanding (cover page) thousands of shares	49,046	49,046	49,046	49,046	49,046	49,046	49,046	49,046	49,046	49,221	49,221	49,221

Cash flows

CSV

Fiscal quarters (MNOV's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(723)	(2,059)*	(2,755)	(2,628)	(2,852)	(2,815)*	(2,864)	(3,281)	(3,050)	(2,802)*	(2,586)	(2,314)
Stock-based compensation	219*	(237)*	215	207*	505*	264*	286	205*	158*	181*	408	177*
Depreciation and amortization	6*	5*	5	5*	5*	5*	5	5*	5*	5*	4	5*
Net cash from operating activities	(1,372)*	(499)*	(3,868)	(2,811)*	(2,032)*	(1,932)*	(3,784)	(2,306)*	(1,703)*	(2,017)*	(3,470)	(1,920)*
Purchases of property and equipment	3*	(0)*	—	—	0*	(0)*	0	0*	3*	0*	11	0*
Net cash from investing activities	(3)*	0*	—	—	0*	0*	0	0*	(3)*	0*	(11)	0*
Proceeds from issuing common stock	—	—	—	—	—	year only	—	—	—	year only	—	—
Net cash from financing activities	—	—	—	—	—	year only	—	—	—	year only	—	—
Net change in cash	(1,369)*	(508)*	(3,861)	(2,801)*	(2,057)*	(1,921)*	(3,788)	(2,312)*	(1,697)*	(1,756)*	(3,477)	(1,913)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Medicinova	25,416	458	(1,920)*	49.2M	13.2 quarters	Q2 FY26 10-QJun 30, 2026
Lifevantage	14,920	42,377*	4,767*	12.5M	—	Q4 FY26 10-KJun 30, 2026
Veru	23,880	not reported	(5,467)*	17.1M	4.4 quarters	Q3 FY26 10-QJun 30, 2026
PDS Biotechnology	5,596	not reported	(2,793)*	56.0M	2.0 quarters	Q2 FY26 10-QJun 30, 2026
Sutro Biopharma	54,335	9,839	(38,290)*	16.6M	4.3 quarters	Q2 FY26 10-QJun 30, 2026
Whitehawk Therapeutics	85,234	0	(14,529)*	57.0M	13.1 quarters	Q2 FY26 10-QJun 30, 2026
iBio	56,395	0*	(6,228)*	64.3M	14.1 quarters	Q4 FY26 10-KJun 30, 2026
Corbus Pharmaceuticals Holdings	23,370	not reported	(29,626)*	19.3M	4.0 quarters	Q2 FY26 10-QJun 30, 2026
Seres Therapeutics	15,594	736	(22,394)*	9.9M	0.7 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.